Lexicon Pharmaceuticals Inc
$ 1.23
4.24%
06 Feb - close price
- Market Cap 513,976,000 USD
- Current Price $ 1.23
- High / Low $ 1.27 / 1.20
- Stock P/E N/A
- Book Value 0.33
- EPS -0.19
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.46 %
- 52 Week High 1.83
- 52 Week Low 0.28
About
Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical leader based in The Woodlands, Texas, focused on developing novel therapies for metabolic and neuroendocrine disorders. The company utilizes its proprietary gene-targeting technologies to advance a promising pipeline of innovative treatments aimed at addressing critical unmet medical needs. With an experienced leadership team and a commitment to scientific excellence, Lexicon is strategically positioned to improve patient outcomes while fostering long-term growth in the rapidly evolving healthcare landscape.
Analyst Target Price
$2.92
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-03-10 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-03-11 | 2023-11-08 | 2023-08-03 | 2023-05-02 | 2023-03-02 |
| Reported EPS | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.2 | -0.2 | -0.21 | -0.22 | -0.17 | -0.16 |
| Estimated EPS | -0.07 | -0.09 | -0.1033 | -0.1248 | -0.16 | -0.19 | -0.2 | -0.22 | -0.21 | -0.17 | -0.18 | -0.13 |
| Surprise | 0.03 | 0.1 | 0.0333 | 0.0348 | -0.02 | 0.02 | 0 | 0.02 | 0 | -0.05 | 0.01 | -0.03 |
| Surprise Percentage | 42.8571% | 111.1111% | 32.2362% | 27.8846% | -12.5% | 10.5263% | 0% | 9.0909% | 0% | -29.4118% | 5.5556% | -23.0769% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LXRX
2026-02-06 22:29:14
Lexicon Pharmaceuticals (LXRX) successfully closed an underwritten public offering and concurrent private placement on February 2, 2026, raising approximately $94.6 million. The funds are earmarked for research and development of drug candidates, as well as for general working capital and corporate purposes. This financing move, while providing capital, has also prompted discussions about potential shareholder dilution.
2026-02-06 22:20:00
Lexicon Pharmaceuticals closed a public offering of 32 million shares of common stock and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares. The shares were priced at $1.30 per common share and $65 per preferred share, with the offerings closing on February 2, 2026. Proceeds will fund research and development and general corporate purposes, and the company granted options for additional share purchases to underwriters and a private purchaser.
2026-02-03 05:28:20
Lexicon Pharmaceuticals has signed three material agreements to raise equity capital. This includes a public offering led by Jefferies and Piper Sandler expected to generate $41.6 million, a private placement with Invus affiliates for $29.12 million in common shares, and a Preferred Stock Purchase Agreement with an Invus affiliate for convertible preferred stock anticipated to add $23.86 million. These actions aim to support liquidity and honor preemptive rights.
2026-02-01 14:02:12
Lexicon Pharmaceuticals has announced an underwritten public stock offering to fund upcoming research and development projects and cover working capital, with Jefferies and Piper Sandler managing the initiative. This move comes as the company's stock has traded down by 18.75% amid cautious investor sentiment and significant profitability issues. While the offering aims to bolster financial strength, the negative financial metrics and potential dilution effect create uncertainty, making diligent oversight of the newly acquired funds vital for long-term viability.
2026-01-31 13:30:01
Lexicon Pharmaceuticals (LXRX) has announced a public stock offering to fund research and development, despite its stock trading down by -18.75% amidst concerns over clinical trial results and regulatory hurdles. The company faces significant financial challenges, evidenced by negative profitability ratios, but possesses a strong gross margin and current ratio. This strategic move, managed by Jefferies and Piper Sandler, aims to provide financial stability and capitalize on future market opportunities, though it may lead to further shareholder dilution and continued bearish pressure in the short term.
2026-01-31 05:30:01
Lexicon Pharmaceuticals has priced a share offering valued at $94.6 million. This financial move indicates the company's efforts to raise capital, likely for operational expenses, research and development, or other strategic initiatives. The specific terms of the offering, such as the price per share and the number of shares being sold, would determine the full scope of this capital injection.
